Previous 10 | Next 10 |
Horizon Therapeutics ( HZNP ) Q4 results : More news on: Horizon Therapeutics Public Limited Company, Healthcare stocks news, Earnings news and commentary, , Read more ...
-- Record Fourth-Quarter 2019 Net Sales of $363.5 Million Driven by 14 Percent Growth in the Orphan and Rheumatology Segment; Fourth-Quarter 2019 GAAP Net Income of $592.8 Million; Adjusted EBITDA of $139.9 Million -- -- Record Full-Year 2019 Net Sales of $1.30 Billion Driven by ...
Horizon Pharma (NASDAQ: HZNP ) is scheduled to announce Q4 earnings results on Wednesday, February 26th, before market open. The consensus EPS Estimate is $0.42 (-37.3% Y/Y) and the consensus Revenue Estimate is $349.25M (-1.8% Y/Y). Over the last 2 years, HZNP has beaten EPS estimate...
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 02/14/2020. Please visit our Tracking John Paulson's Paulson & Company Portfolio serie...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in March: Cowen and Company 40 th Annual Health Care Conference Date: Tuesday, Mar. 3, 2020 Presentation Time: 12 p.m. ET Location: Boston The con...
-- Oral granules in packets provide an additional, tear-open option for people living with cystinosis -- Horizon Therapeutics plc (Nasdaq: HZNP) announced today that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI® (cysteamine bitartrate) delayed-release oral gra...
Safety First: NASCAR driver Johanna Long and her helmet (Credit: Gearheads ) Revisiting Our Revised Security Selection Method Since June 2017, I've run a Marketplace service which has an " investing with a helmet on " approach: I present concentrated portfolios where each security is he...
-- NFL Draft Prospects Participating in ‘Reps for Rare Disease’ Will Help Raise Funds for Research and Awareness Programs -- -- Horizon will match Pledged Donations Through the Company’s #RAREis Program -- Horizon Therapeutics plc (Nasdaq: HZNP) and Uplifting...
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its fourth-quarter and full-year 2019 financial results will be released on Wednesday, Feb. 26, 2020. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial...
Data by YCharts Acer Therapeutics Inc. ( ACER ) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts. The Company's focus is to acquire commercial or near-commercial stage orphan or ultra-orphan drugs to treat rare and ultra-rare diseases with critic...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...